Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.
Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.
Kaken Pharmaceutical Co. Ltd. and Johnson & Johnson (J&J) have entered into a license agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), developed by Kaken.
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.
Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.
Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.
Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
RSS
